Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies develops biopharmaceutical product candidates based on molecules that modulate the melanocortin receptor system. Company news centers on its melanocortin-based obesity programs, including oral small-molecule and peptide MC4R agonists, with focus areas that include hypothalamic obesity and Prader-Willi syndrome.
Recurring updates also cover ocular and retinal disease assets, including PL9643 for dry eye disease and PL9654 and PL9655 for diabetic retinopathy, along with research collaborations, sublicensing agreements, public offerings, reverse-stock-split actions, exchange trading status and financial results.
Palatin Technologies, Inc. (NYSE American: PTN) announced its participation in the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020, at 4:00 p.m. EDT, through a virtual presentation. Carl Spana, President and CEO, will discuss the company's corporate and development updates. Interested parties can access the webcast via the official website or by following the provided link. The presentation will be available for replay for 90 days.
Palatin Technologies, Inc. (NYSE American: PTN) participated in Canaccord Genuity's 40th Annual Growth Conference on August 13, 2020, engaging in a Fireside Chat hosted by John Newman. CEO Carl Spana and CFO Stephen T. Wills represented the company during the virtual event. The discussion focused on Palatin's specialized biopharmaceutical developments, particularly its first-in-class medicines targeting melanocortin and natriuretic peptide receptor systems. A webcast replay is available on the company's website for 90 days.
Palatin Technologies (NYSE American: PTN) announced the completion of patient enrollment for its Phase 2 study of PL9643 aimed at treating dry eye disease (DED). The study, which resumed enrollment after COVID-19 delays, aims to evaluate PL9643's efficacy and safety compared to a placebo. With data readout expected in Q4 2020, Palatin emphasizes the potential of PL9643 to offer a quick onset of efficacy and a favorable safety profile, addressing the needs of patients who struggle with existing therapies for DED.
Palatin Technologies (PTN) announced the mutual termination of its January 2017 license agreement with AMAG Pharmaceuticals, regaining North American rights to Vyleesi® (bremelanotide), the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. AMAG will pay Palatin $12 million at closing and $4.3 million on March 31, 2021. Palatin will take over Vyleesi's manufacturing and commercialization, ensuring uninterrupted patient access. The company aims to explore strategic partnerships to enhance Vyleesi's marketing, stressing its commitment to affordable access for women affected by HSDD.
Palatin Technologies (NYSE American: PTN) announced the development of PL8177 as a potential treatment for COVID-19 patients experiencing hypoxemic respiratory failure. The decision is based on positive preclinical results showing PL8177's efficacy in reducing inflammation and lung damage. The company plans to submit an IND application in Q3 2020 and initiate a Phase 2 trial in Q4 2020, following successful preclinical and Phase 1 studies. The trial will evaluate the effectiveness of PL8177 against a placebo in hospitalized adult patients with severe COVID-19 symptoms.